Astellas Pharma Inc. and UMN Pharma Inc. announced today that the both companies entered into the definitive agreement for UMN-0501 and UMN-0502, which are cell culture based influenza vaccine programs developed by UMN Pharma, on September 21, 2010. Under the agreement, the both companies will co-develop the Licensed Programs and Astellas will exclusively commercialize them in Japan. The execution of a memorandum of understandings as of August 16, 2010 was already announced on August 17, 2010.